Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102742 | 0.85 | IRAK4 (0.46) | IRAK4PAK4PIKFYVE | |
| SCHEMBL12525017 | 0.82 | PAK4 (0.59) | IRAK4PAK4PIKFYVEPIM3TTBK1 | |
| SCHEMBL3824181 | 0.81 | MKNK1 (0.48) | IRAK4PAK4PIKFYVE | |
| SCHEMBL5090382 | 0.79 | KDR (0.47) | IRAK4PAK4PIKFYVE | |
| SCHEMBL5102172 | 0.77 | IRAK4 (0.49) | IRAK4PAK4PIKFYVEPIM3 | |
| SCHEMBL5096332 | 0.77 | ROCK1 (0.42) | IRAK4 | |
| SCHEMBL30459759 | 0.74 | ROCK1 (0.45) | PIM3TTBK1 | |
| SCHEMBL17683138 | 0.74 | ROCK1 (0.45) | PIM3TTBK1 | |
| SCHEMBL7024457 | 0.74 | LCK (0.55) | — | |
| SCHEMBL17683111 | 0.73 | LRRK2 (0.42) | IRAK4PIM3TTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | IRAK4 447/4885PAK4 245/4885PIKFYVE 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.